Immunotherapy drugs for prostate cancer
Immunotherapy for Prostate Cancer: Educational Overview
I'd be happy to explain how immunotherapy is being used in prostate cancer treatment. Let me break this down for you.
Standard Medical Guidance
According to NCCN Guidelines for Prostate Cancer, immunotherapy has a limited but growing role:
Current FDA-Approved Immunotherapy Approaches:
-
Checkpoint Inhibitors (Pembrolizumab)
- FDA approved for metastatic castration-resistant prostate cancer (mCRPC) with specific biomarkers
- Used in patients whose tumors have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
- These are relatively rare in prostate cancer (~3-5% of cases)
-
Combination Approaches
- Checkpoint inhibitors combined with other therapies (like hormone therapy or chemotherapy) are being studied
- Some combinations show promise in clinical trials
-
Therapeutic Cancer Vaccines
- Sipuleucel-T (Provenge) - an FDA-approved therapeutic vaccine for metastatic castration-resistant prostate cancer
- Works differently than checkpoint inhibitors; trains the immune system to recognize cancer cells
Why Immunotherapy Has Limited Use in Prostate Cancer:
- Prostate cancer is generally considered "immunologically cold" (doesn't naturally attract immune cells)
- Most prostate cancers don't have the biomarkers that make immunotherapy effective
- Hormone therapy and chemotherapy remain the standard approaches for most patients
Questions to Ask Your Oncologist
If you or a loved one has been diagnosed with prostate cancer, consider asking:
- "Has my tumor been tested for MSI-H or mismatch repair deficiency?" (This determines immunotherapy eligibility)
- "Based on my specific cancer stage and biomarkers, is immunotherapy an option for my treatment plan?"
- "Are there clinical trials available that combine immunotherapy with other treatments?"
- "What are the standard treatment options for my specific situation, and how do they compare to immunotherapy?"
- "What side effects should I expect with any immunotherapy approach, and how are they managed?"
Where to Learn More
- NCCN Guidelines for Prostate Cancer (nccn.org) - Updated regularly with latest recommendations
- American Cancer Society - Prostate cancer treatment information
- NCI Cancer Information Service - 1-800-4-CANCER for personalized questions
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated November 28, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about General
- How does immunotherapy work for cancer
- Repurposed drug schedule for metastatic breast cancer
- What are side effects of immunotherapy
- What iS aBAT THERAPY for prostate cancer
- What are the innovative cancer treatment for prostate cancer
- What should I ask my oncologist before starting immunotherapy
- What is the difference between chemotherapy and immunotherapy
- Can I exercise during prostate cancer radiation